KRAS and neoplasm: Vehicle-treated tumor-bearing mice served as the control group, while Brusatol-treated mice showed markedly reduced Nrf2, BCL-2, Ki67, and KRAS expression in metastatic liver nodules [15, 31] (Fig. 6e).